Last reviewed · How we verify
alpha blocker monotherapy
The alpha blocker monotherapy developed by Samsung Medical Center is not approved by the FDA and lacks a formal label. This drug acts as an alpha-adrenergic receptor antagonist, which can help in conditions like hypertension and benign prostatic hyperplasia. However, due to its lack of FDA approval, it is primarily used off-label. The drug's safety profile includes several common side effects, but specific details on rates and severity are limited. Commercially, the drug has not been launched, and there is no current revenue or peak sales estimate available.
At a glance
| Generic name | alpha blocker monotherapy |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Alpha blocker |
| Target | alpha-1 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Drug interactions
- CYP3A4 inhibitors
- Diuretics
Key clinical trials
- REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men (NA)
- A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic Hyperplasia
- Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial (NA)
- (Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia (NA)
- Efficacy of α-blocker or 5-ARI Withdrawal to Continued Combination Therapy on the Maintenance of LUTS in Men With BPH (PHASE3)
- Detrol LA In Men With Overactive Bladder. (PHASE4)
- Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) (PHASE4)
- Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- alpha blocker monotherapy CI brief — competitive landscape report
- alpha blocker monotherapy updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI